The clinical-stage biopharma Acelyrin has appointed Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals (Nasdaq:JAZZ), to its board of directors.
Cozadd co-founded Jazz Pharmaceuticals in 2003. Last year, the company brought in $3 billion in revenue. Cozadd continues to serve as the company’s chairperson and CEO.
Before taking the helm of Jazz Pharmaceuticals, Cozadd served as the chief operating officer of Alza Corp., which merged with Johnson & Johnson in 2001.
He is currently a member of the board of the Biotechnology Innovation Organization (BIO) and also serves on the boards of two non-profits.
“His success as a biopharma leader has given hope to patients around the world, and his perspectives will help Acelyrin build our capabilities, drive growth for our investors, and realize our vision of accelerating the development of life-changing medicines to help patients with serious diseases,” Lin added.
Co-founder and CEO of Acelyrin Dr. Shao-Lee Lin said, “I am delighted to welcome Bruce to our board of directors.”In November 2021, Acelyrin closed $250 million in Series B financing.
At that time, it also announced the announced licensing of izokibep, a late-stage IL-17A inhibitor to treat inflammatory diseases.
Phase 2 trials of izokibep focus on conditions such as ankylosing spondylitis, axial spondylarthritis, hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis and uveitis.
Filed Under: Drug Discovery, Drug Discovery and Development